[go: up one dir, main page]

AR039423A1 - Poliformo del acido 4-(2-(4-(1-(2-etoxietil)-1h-bencimidazol-2-il)-1-piperidinil)etil)-alfa,alfa-dimetil-bencenoacetico - Google Patents

Poliformo del acido 4-(2-(4-(1-(2-etoxietil)-1h-bencimidazol-2-il)-1-piperidinil)etil)-alfa,alfa-dimetil-bencenoacetico

Info

Publication number
AR039423A1
AR039423A1 ARP030101325A ARP030101325A AR039423A1 AR 039423 A1 AR039423 A1 AR 039423A1 AR P030101325 A ARP030101325 A AR P030101325A AR P030101325 A ARP030101325 A AR P030101325A AR 039423 A1 AR039423 A1 AR 039423A1
Authority
AR
Argentina
Prior art keywords
polymorph
dimethyl
acid
poliform
etoxietil
Prior art date
Application number
ARP030101325A
Other languages
English (en)
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of AR039423A1 publication Critical patent/AR039423A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe el polimorfo 1 de ácido 4-[2-[4-[1-(2-etoxietil)-1H-bencimidazol-2-il]-1-piperidinil]etil]-a, a-dimetil-bencenoacético de fórmula (1), procedimientos para su preparación, formulaciones farmacéuticas conteniendo el polimorfo 1 y la utilización del polimorfo 1 para el tratamiento de reacciones alérgicas y de procesos patológicos mediados por la histamina en mamíferos, tales como el hombre. Reivindicación 1: Polimorfo 1 de la bilastina caracterizado mediante su análisis cristalográfico de rayos-X, con parámetros de cristal que son aproximadamente iguales a los siguientes: Sistema cristalográfico Monoclínico Grupo espacial P2(1)/c Tamano del cristal 0,56 x 0,45 x 0,24 mm Dimensión de la celda a = 23,38(5) L (angstrom) b = 8,829(17) L c = 12,59(2) L a = 90s b = 90s g = 90s Volumen 2600(8) A3 Z, Densidad calculada 4; 1,184 mg/m3
ARP030101325A 2002-04-19 2003-04-15 Poliformo del acido 4-(2-(4-(1-(2-etoxietil)-1h-bencimidazol-2-il)-1-piperidinil)etil)-alfa,alfa-dimetil-bencenoacetico AR039423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (1)

Publication Number Publication Date
AR039423A1 true AR039423A1 (es) 2005-02-16

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101325A AR039423A1 (es) 2002-04-19 2003-04-15 Poliformo del acido 4-(2-(4-(1-(2-etoxietil)-1h-bencimidazol-2-il)-1-piperidinil)etil)-alfa,alfa-dimetil-bencenoacetico

Country Status (30)

Country Link
US (2) US7612095B2 (es)
EP (1) EP1505066B1 (es)
JP (1) JP5142448B2 (es)
KR (1) KR100673140B1 (es)
CN (1) CN1290843C (es)
AR (1) AR039423A1 (es)
AT (1) ATE347550T1 (es)
AU (1) AU2002255017B2 (es)
BG (1) BG66302B1 (es)
BR (1) BRPI0215703B8 (es)
CA (1) CA2484460C (es)
CY (2) CY1107564T1 (es)
CZ (1) CZ305162B6 (es)
DE (1) DE60216641T2 (es)
DK (1) DK1505066T3 (es)
ES (1) ES2278018T3 (es)
HR (1) HRP20041048B1 (es)
HU (1) HU230032B1 (es)
IL (1) IL164645A (es)
MX (1) MXPA04010313A (es)
NO (1) NO329327B1 (es)
NZ (1) NZ536551A (es)
PA (1) PA8571201A1 (es)
PE (1) PE20040086A1 (es)
PT (1) PT1505066E (es)
SI (1) SI1505066T1 (es)
SK (1) SK288052B6 (es)
UA (1) UA76866C2 (es)
UY (1) UY27762A1 (es)
WO (1) WO2003089425A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
LT3327012T (lt) 2015-07-24 2021-09-10 Urquima, S.A. Bilastino kristalinės formos ir jų gamybos būdai
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
WO2019097091A1 (en) 2017-12-18 2019-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
US20210128544A1 (en) 2018-01-18 2021-05-06 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
EP4267109A1 (en) 2020-12-23 2023-11-01 Noucor Health S.A. A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
MXPA01010472A (es) * 1999-04-16 2002-05-06 Reddy Research Foundation Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt

Also Published As

Publication number Publication date
CY2013015I2 (el) 2015-08-05
EP1505066B1 (en) 2006-12-06
CY2013015I1 (el) 2015-08-05
PA8571201A1 (es) 2003-12-10
IL164645A0 (en) 2005-12-18
ES2278018T3 (es) 2007-08-01
WO2003089425A1 (es) 2003-10-30
BRPI0215703B1 (pt) 2017-06-27
JP5142448B2 (ja) 2013-02-13
US20100004285A1 (en) 2010-01-07
DK1505066T3 (da) 2007-03-19
CZ305162B6 (cs) 2015-05-27
CN1628112A (zh) 2005-06-15
NO20044999L (no) 2005-01-14
NZ536551A (en) 2006-08-31
EP1505066A1 (en) 2005-02-09
SI1505066T1 (sl) 2007-04-30
PE20040086A1 (es) 2004-04-27
AU2002255017A1 (en) 2003-11-03
DE60216641D1 (de) 2007-01-18
CY1107564T1 (el) 2013-03-13
DE60216641T2 (de) 2007-09-27
KR20050005448A (ko) 2005-01-13
CZ20041122A3 (cs) 2005-03-16
IL164645A (en) 2010-11-30
MXPA04010313A (es) 2005-06-08
HRP20041048A9 (hr) 2013-01-31
HRP20041048B1 (hr) 2013-04-30
SK50202004A3 (sk) 2005-05-05
HUP0500241A2 (hu) 2005-06-28
CA2484460C (en) 2009-09-29
US20050203141A1 (en) 2005-09-15
HU230032B1 (hu) 2015-05-28
HK1072772A1 (en) 2005-09-09
ATE347550T1 (de) 2006-12-15
NO329327B1 (no) 2010-09-27
PT1505066E (pt) 2007-03-30
BG66302B1 (bg) 2013-03-29
CN1290843C (zh) 2006-12-20
BR0215703A (pt) 2005-02-01
AU2002255017B2 (en) 2008-11-13
CA2484460A1 (en) 2003-10-30
UY27762A1 (es) 2003-09-30
KR100673140B1 (ko) 2007-01-22
JP2005529120A (ja) 2005-09-29
BG108941A (en) 2005-12-30
SK288052B6 (sk) 2013-03-01
HRP20041048A2 (en) 2005-02-28
US7612095B2 (en) 2009-11-03
BRPI0215703B8 (pt) 2021-05-25
UA76866C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
AR039423A1 (es) Poliformo del acido 4-(2-(4-(1-(2-etoxietil)-1h-bencimidazol-2-il)-1-piperidinil)etil)-alfa,alfa-dimetil-bencenoacetico
US11220477B2 (en) Modulators of the eIF2alpha pathway
US10864196B2 (en) Modulators of the integrated stress pathway
NO20090328L (no) Nye forbindelser 385
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
EA006707B1 (ru) Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
DK2536285T3 (en) Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
CA2856831A1 (en) Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
PE20130340A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp)
US9062041B2 (en) 2H-indazoles as EP2 receptor antagonists
ES2645970T3 (es) Inhibidores de agrecanasa
ES2770047T3 (es) Compuestos de azetidiniloxifenilpirrolidina
EP2864296A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
EP2780321B1 (en) Mono-fluoro beta-secretase inhibitors
CN116075513A (zh) Nek7激酶的抑制剂
EP4153160A1 (en) Benzoylhydrazide-derived hdac degraders as therapeutics for treating cancer and other human diseases
JP7426939B2 (ja) 置換ベンゾジアゾールおよび療法におけるその使用
CN113563244B (zh) 取代的氮杂五元环类化合物及其在药物中的应用
US20170029388A1 (en) Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto
EP3160949A1 (en) Enzyme interacting agents
WO2021163572A1 (en) Novel tdzd analogs as agents that delay, prevent, or reverse age-associated diseases; and as anti-cancer and antileukemic agents
AR060307A1 (es) Medicamentos
Zhang et al. Design, Synthesis, Structure–Activity Relationships, and Docking Studies of 1‐(γ‐1, 2, 3‐Triazol Substituted Prolyl)‐(S)‐3, 3‐Difluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidase‐4 Inhibitors
AR074737A1 (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il) metanona-n-carboxamida y composicion farmaceutica que los contiene

Legal Events

Date Code Title Description
FC Refusal